In 2023, the sales of nervous system medicines in Canada were 5.64 billion USD. For the forecasted period from 2024 to 2028, sales are expected to grow steadily, starting at 5.79 billion USD in 2024 and reaching 6.37 billion USD by 2028, reflecting an average Compound Annual Growth Rate (CAGR) of around 2.4%. The year-on-year growth rate shows a consistent upward trend, between 2.5% and 2.8% annually over the period, indicating a robust demand for nervous system treatments in the Canadian market.

Future trends to watch for include:

Advancements in personalized medicine and its impact on nervous system treatments.
The increasing prevalence of neurological disorders and its influence on market growth.
Potential regulatory changes affecting product pricing and accessibility.
Emerging therapies and biotechnological innovations in this field.